Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Alteplase | The risk or severity of angioedema can be increased when Alteplase is combined with Lanoteplase. |
| Urokinase | The risk or severity of angioedema can be increased when Urokinase is combined with Lanoteplase. |
| Reteplase | The risk or severity of angioedema can be increased when Reteplase is combined with Lanoteplase. |
| Anistreplase | The risk or severity of angioedema can be increased when Anistreplase is combined with Lanoteplase. |
| Tenecteplase | The risk or severity of angioedema can be increased when Tenecteplase is combined with Lanoteplase. |
| Streptokinase | The risk or severity of angioedema can be increased when Streptokinase is combined with Lanoteplase. |
| Valsartan | The risk or severity of angioedema can be increased when Valsartan is combined with Lanoteplase. |
| Ramipril | The risk or severity of angioedema can be increased when Ramipril is combined with Lanoteplase. |
| Pregabalin | The risk or severity of angioedema can be increased when Pregabalin is combined with Lanoteplase. |
| Conjugated estrogens | The risk or severity of angioedema can be increased when Conjugated estrogens is combined with Lanoteplase. |
| Fosinopril | The risk or severity of angioedema can be increased when Fosinopril is combined with Lanoteplase. |
| Trandolapril | The risk or severity of angioedema can be increased when Trandolapril is combined with Lanoteplase. |
| Benazepril | The risk or severity of angioedema can be increased when Benazepril is combined with Lanoteplase. |
| Enalapril | The risk or severity of angioedema can be increased when Enalapril is combined with Lanoteplase. |
| Diclofenac | The risk or severity of angioedema can be increased when Diclofenac is combined with Lanoteplase. |
| Losartan | The risk or severity of angioedema can be increased when Losartan is combined with Lanoteplase. |
| Moexipril | The risk or severity of angioedema can be increased when Moexipril is combined with Lanoteplase. |
| Lisinopril | The risk or severity of angioedema can be increased when Lisinopril is combined with Lanoteplase. |
| Perindopril | The risk or severity of angioedema can be increased when Perindopril is combined with Lanoteplase. |
| Eprosartan | The risk or severity of angioedema can be increased when Eprosartan is combined with Lanoteplase. |
| Sirolimus | The risk or severity of angioedema can be increased when Sirolimus is combined with Lanoteplase. |
| Quinapril | The risk or severity of angioedema can be increased when Quinapril is combined with Lanoteplase. |
| Omapatrilat | The risk or severity of angioedema can be increased when Omapatrilat is combined with Lanoteplase. |
| Acetylsalicylic acid | The risk or severity of angioedema can be increased when Acetylsalicylic acid is combined with Lanoteplase. |
| Telmisartan | The risk or severity of angioedema can be increased when Telmisartan is combined with Lanoteplase. |
| Ibuprofen | The risk or severity of angioedema can be increased when Ibuprofen is combined with Lanoteplase. |
| Rescinnamine | The risk or severity of angioedema can be increased when Rescinnamine is combined with Lanoteplase. |
| Captopril | The risk or severity of angioedema can be increased when Captopril is combined with Lanoteplase. |
| Sitagliptin | The risk or severity of angioedema can be increased when Sitagliptin is combined with Lanoteplase. |
| Cilazapril | The risk or severity of angioedema can be increased when Cilazapril is combined with Lanoteplase. |
| Forasartan | The risk or severity of angioedema can be increased when Forasartan is combined with Lanoteplase. |
| Saprisartan | The risk or severity of angioedema can be increased when Saprisartan is combined with Lanoteplase. |
| Spirapril | The risk or severity of angioedema can be increased when Spirapril is combined with Lanoteplase. |
| Vildagliptin | The risk or severity of angioedema can be increased when Vildagliptin is combined with Lanoteplase. |
| AMG-222 | The risk or severity of angioedema can be increased when AMG-222 is combined with Lanoteplase. |
| Bisegliptin | The risk or severity of angioedema can be increased when Bisegliptin is combined with Lanoteplase. |
| Icatibant | The risk or severity of angioedema can be increased when Icatibant is combined with Lanoteplase. |
| Alogliptin | The risk or severity of angioedema can be increased when Alogliptin is combined with Lanoteplase. |
| Temsirolimus | The risk or severity of angioedema can be increased when Lanoteplase is combined with Temsirolimus. |
| Saxagliptin | The risk or severity of angioedema can be increased when Lanoteplase is combined with Saxagliptin. |
| Amediplase | The risk or severity of angioedema can be increased when Lanoteplase is combined with Amediplase. |
| Gosogliptin | The risk or severity of angioedema can be increased when Lanoteplase is combined with Gosogliptin. |
| Azilsartan medoxomil | The risk or severity of angioedema can be increased when Lanoteplase is combined with Azilsartan medoxomil. |
| Temocapril | The risk or severity of angioedema can be increased when Lanoteplase is combined with Temocapril. |
| Linagliptin | The risk or severity of angioedema can be increased when Lanoteplase is combined with Linagliptin. |
| Sacubitril | The risk or severity of angioedema can be increased when Lanoteplase is combined with Sacubitril. |
| Enalaprilat | The risk or severity of angioedema can be increased when Lanoteplase is combined with Enalaprilat. |
| Dutogliptin | The risk or severity of angioedema can be increased when Lanoteplase is combined with Dutogliptin. |
| Imidapril | The risk or severity of angioedema can be increased when Lanoteplase is combined with Imidapril. |
| Teneligliptin | The risk or severity of angioedema can be increased when Lanoteplase is combined with Teneligliptin. |
| Omarigliptin | The risk or severity of angioedema can be increased when Lanoteplase is combined with Omarigliptin. |
| Carmegliptin | The risk or severity of angioedema can be increased when Lanoteplase is combined with Carmegliptin. |
| Gemigliptin | The risk or severity of angioedema can be increased when Lanoteplase is combined with Gemigliptin. |
| Anagliptin | The risk or severity of angioedema can be increased when Lanoteplase is combined with Anagliptin. |
| Evogliptin | The risk or severity of angioedema can be increased when Lanoteplase is combined with Evogliptin. |
| Zofenopril | The risk or severity of angioedema can be increased when Lanoteplase is combined with Zofenopril. |
| Delapril | The risk or severity of angioedema can be increased when Lanoteplase is combined with Delapril. |
| Saruplase | The risk or severity of angioedema can be increased when Lanoteplase is combined with Saruplase. |
| Benazeprilat | The risk or severity of angioedema can be increased when Lanoteplase is combined with Benazeprilat. |
| Fosinoprilat | The risk or severity of angioedema can be increased when Lanoteplase is combined with Fosinoprilat. |
| Ramiprilat | The risk or severity of angioedema can be increased when Lanoteplase is combined with Ramiprilat. |
| Trandolaprilat | The risk or severity of angioedema can be increased when Lanoteplase is combined with Trandolaprilat. |
| Moexiprilat | The risk or severity of angioedema can be increased when Lanoteplase is combined with Moexiprilat. |
| Perindoprilat | The risk or severity of angioedema can be increased when Lanoteplase is combined with Perindoprilat. |
| Quinaprilat | The risk or severity of angioedema can be increased when Lanoteplase is combined with Quinaprilat. |
| Quinoline Yellow WS | The risk or severity of angioedema can be increased when Lanoteplase is combined with Quinoline Yellow WS. |
| Alpha-1-proteinase inhibitor | The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Lanoteplase. |
| Menadione | The therapeutic efficacy of Menadione can be decreased when used in combination with Lanoteplase. |
| Tranexamic acid | The therapeutic efficacy of Tranexamic acid can be decreased when used in combination with Lanoteplase. |
| Aminocaproic acid | The therapeutic efficacy of Aminocaproic acid can be decreased when used in combination with Lanoteplase. |
| Aprotinin | The therapeutic efficacy of Aprotinin can be decreased when used in combination with Lanoteplase. |
| Hydrogen peroxide | The therapeutic efficacy of Hydrogen peroxide can be decreased when used in combination with Lanoteplase. |
| Aminomethylbenzoic acid | The therapeutic efficacy of Aminomethylbenzoic acid can be decreased when used in combination with Lanoteplase. |
| Camostat | The therapeutic efficacy of Camostat can be decreased when used in combination with Lanoteplase. |
| Menadione bisulfite | The therapeutic efficacy of Menadione bisulfite can be decreased when used in combination with Lanoteplase. |